IL stock · Healthcare sector · Drug Manufacturers—Specialty & Generic
Company Logo

Teva Pharmaceutical Industries Limited

TEVANYSE

7.90

USD
-0.16
(-1.99%)
Market Closed
-69.16P/E
3Forward P/E
-3.45P/E to S&P500
8.995BMarket CAP
- -Div Yield

Teva Pharmaceutical Industries Limited

NYSE:TEVA

RECENT
PRICE

7.90

P/E
RATIO

-69.16

(PEG:- -)

P/E RATIO
RELATIVE
TO S&P

-3.45

DIV
YLD

0.00%

High:
Low:

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

Legends

Stock price

1.27 Beta (1.0 Market)

0

0

0

0

0

0

0

0

0

-

% total return 09/22:

Stock

S&P

1y.

0

0

3y.

0

0

5y.

0

0

0

Percent shares traded:

0

0

0

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

TTM

Fiscal year

11.12

0.72

2.21

0.30

12.25

2.54

1.65

0.39

14.21

0.81

3.27

0.50

15.94

2.29

3.04

0.61

17.99

3.72

3.82

0.75

20.58

3.10

3.46

0.90

23.30

2.25

3.98

0.98

23.93

1.49

2.60

1.28

23.77

3.58

4.92

1.36

22.98

1.86

5.58

1.35

22.94

0.34

4.53

1.63

22.03

(16.01)

2.59

1.14

18.47

(2.11)

1.76

0.02

15.48

(0.92)

0.20

0.05

15.21

(3.64)

0.58

- -

14.50

0.38

0.22

- -

10.54

0.12

0.43

- -

Revenue per share

Earnings per share

Free Cash Flow per sh

Dividends per share

0.52

14.74

0.71

17.87

0.87

20.90

0.82

22.04

0.79

24.49

1.18

24.94

1.27

26.11

1.21

26.58

1.09

27.33

0.90

34.82

0.94

34.91

0.86

17.09

0.64

14.40

0.48

12.81

0.53

9.16

0.51

9.39

0.53

9.25

CAPEX per share

Book Value per share

756

768

780

872

896

890

872

849

853

855

955

1,016

1,021

1,091

1,095

1,095

1,103

Comm.Shares outs.(m)

50.5

2.8

0.8%

15.9

0.9

1.0%

55.4

2.6

1.1%

21.1

0.3

1.3%

14.8

0.7

1.4%

14.7

0.9

2.0%

18.5

1.2

2.3%

26.1

1.5

3.3%

14.4

0.8

2.6%

33.1

1.7

2.2%

148.0

6.7

3.2%

(1.6)

(0.1)

4.3%

(10.0)

(0.4)

0.1%

(12.6)

(0.5)

0.4%

(2.9)

(0.1)

- -

26.5

0.9

- -

(69.2)

(3.5)

- -

Avg. annual P/E ratio

P/E relative to S&P500

Avg. annual div. yield

Capital Structure (30/6/22 | Q2)

Total liabilities
$36,104 m.

Total assets
$45,932 m.

Long-term debt
$20,734 m.

Cash and equiv.
$2,058 m.

Goodwill $18,837 m.

Retained earnings $(10,529) m.

Common stock 1,103 m. shares

Market Capitalisation
$8,995 m. (as of 26/9/22)

18,312

17.0%

20,317

10.9%

20,314

8.1%

20,272

19.5%

19,652

17.1%

21,903

9.8%

22,385

(78.1)%

18,854

(8.7)%

16,887

(2.6)%

16,658

(21.4)%

15,879

10.8%

11,627

4.5%

Revenue (m)

Operating margin

1,069

2,759

1,708

1,963

1,642

1,269

1,508

3,055

1,308

1,588

1,524

329

2,112

(16,265)

1,842

(2,150)

1,722

(999)

1,557

(3,990)

1,330

417

1,330

133

Depreciation (m)

Net profit (m)

4.3%

15.1%

(7.5)%

9.7%

(3.4)%

6.2%

16.2%

15.1%

27.0%

8.1%

63.2%

1.5%

10.5%

(72.7)%

7.5%

(11.4)%

22.0%

(5.9)%

3.8%

(24.0)%

32.1%

2.6%

- -

0.9%

Income tax rate

Net profit margin

606

10,236

22,195

3,467

11,712

22,768

1,755

10,387

22,565

2,107

8,566

23,313

5,393

8,383

29,769

(1,558)

32,524

33,337

(2,539)

28,829

17,359

(528)

26,700

14,707

(210)

24,997

13,972

(159)

23,210

10,026

1,546

22,033

10,278

1,168

20,734

9,828

Working capital (m)

Long-term debt (m)

Equity (m)

8.0%

6.1%

12.4%

6.2%

4.3%

8.6%

4.5%

3.2%

5.6%

9.7%

8.5%

13.1%

4.4%

4.6%

5.3%

0.7%

1.5%

1.0%

(30.2)%

(25.0)%

(93.7)%

(2.9)%

(2.4)%

(14.6)%

(0.7)%

(0.7)%

(7.2)%

(8.4)%

(6.4)%

(39.8)%

2.9%

3.3%

4.1%

- -

1.1%

1.4%

ROIC

Return on capital

Return on equity

Working Capital

2019

2020

2021

Cash assets

1,975

2,177

2,165

Receivables

5,676

4,581

4,529

Inventory

4,422

4,403

3,818

Other

1,391

1,844

2,061

Current assets

13,464

13,005

12,573

Acc. Payable

1,718

1,756

1,686

Debt due

2,345

3,188

1,426

Other

9,611

8,220

7,915

Current liab.

13,674

13,164

11,027

71.0%

55.1%

56.4%

58.1%

14.2%

71.9%

62.2%

39.4%

27.3%

(35.6)%

(373.6)%

28.4%

107.1%

- -

101.0%

- -

105.2%

- -

100.0%

- -

100.0%

- -

100.0%

- -

Plowback ratio

Div.&Repurch. to FCF

Teva Pharmaceutical Industries Limited (IL) started trading on February 1, 2013 (cik: 0000818686), operates in the Healthcare sector (Drug Manufacturers—Specialty & Generic industry), has 34,713 full-time employees, and is led by Mr. Kre Schultz. Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.

Annual rates

(avg rate of change)

Past
5 y.

Past
10 y.

Revenues

-8.06%

-2.43%

Cash flow

0.92%

2.53%

Earnings

12.16%

-557.45%

Dividends

- -

- -

Book value

-11.50%

-5.76%

Insider trading

Type

Shares

Date

Kalif Eliyahu Sharon

Sale

55,500

08/22/22

Shani Eli

Exempt

1,581

08/10/22

Shani Eli

Exempt

1,581

08/10/22

Zaks Tal Zvi

Award

15,810

08/04/22

Satchi-Fainaro Ronit

Award

15,810

08/04/22

Fiscal Year Ends

Quarterly Revenue (m)

Full fiscal year

I

II

III

IV

2020

4,357

3,870

3,978

4,452

16,657

2021

3,982

3,910

3,886

4,100

15,878

2022

1,737

1,904

- -

- -

- -

Fiscal Year Ends

Earnings per share

Full fiscal year

I

II

III

IV

2020

0.06

0.13

(3.97)

0.14

-3.64

2021

0.07

0.19

0.27

(0.15)

0.38

2022

- -

- -

- -

- -

- -

Fiscal Year Ends

Quarterly dividends paid

Full fiscal year

I

II

III

IV

2020

- -

- -

- -

- -

- -

2021

- -

- -

- -

- -

- -

2022

- -

- -

- -

- -

- -

04/18/2022

J&J Settles With West Virginia in Opioid Suit for $99 Million

The Wall Street Journal - Read more...

12/31/2021

Teva Found Liable for Fueling Opioid Addiction in New York

The Wall Street Journal - Read more...